Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov;22(11):2018-2025.
doi: 10.1002/ejhf.2005. Epub 2020 Oct 7.

Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan

Nasrien E Ibrahim  1   2 , Ileana L Piña  3 , Alexander Camacho  1 , Devavrat Bapat  1 , G Michael Felker  4 , Alan S Maisel  5 , Javed Butler  6 , Margaret F Prescott  7 , Cheryl A Abbas  7 , Scott D Solomon  2   8 , James L Januzzi Jr  1   2   9 ; Prospective Study of Biomarkers, Symptom Improvement and Ventricular Remodeling During Entresto Therapy for Heart Failure (PROVE-HF) Study Investigators
Affiliations

Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan

Nasrien E Ibrahim et al. Eur J Heart Fail. 2020 Nov.

Abstract

Aims: We sought to determine sex-based differences in biomarkers, self-reported health status, and magnitude of longitudinal changes in measures of reverse cardiac remodelling among patients with heart failure with reduced ejection fraction (HFrEF, left ventricular ejection fraction ≤40%) treated with sacubitril/valsartan (S/V).

Methods and results: This was a subgroup analysis of patients initiated on S/V in the Prospective Study of Biomarkers, Symptom Improvement and Ventricular Remodeling During Entresto Therapy for Heart Failure (PROVE-HF) study. There were 226 (28.5%) women in the study. Though women had lower baseline N-terminal pro B-type natriuretic peptide (NT-proBNP), they had more rapid early reduction in the biomarker after initiation of S/V. Compared to men, women had lower average baseline Kansas City Cardiomyopathy Questionnaire (KCCQ)-23 Total Symptom score (67.6 vs. 71.9; P = 0.003) but showed greater linear improvement (7.4 vs. 5.5 points; P < 0.001) and faster pace of KCCQ change (P < 0.001) over the course of the trial. Women and men demonstrated similar degrees of reverse left ventricular remodelling following S/V initiation; however, women did so earlier than men with more consistent changes. These results remained unchanged with adjustment for relevant covariates. Reduction in NT-proBNP was associated with reverse cardiac remodelling in both women and men. Treatment with S/V was well tolerated in all.

Conclusions: In women with HFrEF, treatment with S/V was associated with significant NT-proBNP reduction, health status improvement and reverse cardiac remodelling.

Keywords: Biomarkers; Heart failure; Remodelling; Sacubitril/valsartan.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study flow for the present analysis. We sought to characterize baseline and cross‐sectional values as well as longitudinal aspects of change in N‐terminal pro B‐type natriuretic peptide (NT‐proBNP), health status, and cardiac remodelling parameters. KCCQ‐23 TS, Kansas City Cardiomyopathy Questionnaire‐23 Total Symptom score; LVEF, left ventricular ejection fraction.
See this image and copyright information in PMC

References

    1. Gori M, Lam CS, Gupta DK, Santos AB, Cheng S, Shah AM, Claggett B, Zile MR, Kraigher‐Krainer E, Pieske B, Voors AA, Packer M, Bransford T, Lefkowitz M, McMurray J, Solomon SD; PARAMOUNT Investigators . Sex‐specific cardiovascular structure and function in heart failure with preserved ejection fraction. Eur J Heart Fail 2014;16:535–542. - PubMed
    1. Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS. Long‐term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1397–1402. - PubMed
    1. Luchner A, Bröckel U, Muscholl M, Hense HW, Döring A, Riegger GA, Schunkert H. Gender‐specific differences of cardiac remodeling in subjects with left ventricular dysfunction: a population‐based study. Cardiovasc Res 2002;53:720–727. - PubMed
    1. Lam CS, Arnott C, Beale AL, Chandramouli C, Hilfiker‐Kleiner D, Kaye DM, Ky B, Santema BT, Sliwa K, Voors AA. Sex differences in heart failure. Eur Heart J 2019;40:3859–3868c. - PubMed
    1. Aimo A, Gaggin HK, Barison A, Emdin M, Januzzi JL Jr. Imaging, biomarker, and clinical predictors of cardiac remodeling in heart failure with reduced ejection fraction. JACC Heart Fail 2019;7:782–794. - PubMed

Publication types